Open Access Articles- Top Results for Eslicarbazepine acetate

Eslicarbazepine acetate

Eslicarbazepine acetate
File:Eslicarbazepine acetate structure.svg
Systematic (IUPAC) name
(S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide
Clinical data
  • C
Pharmacokinetic data
Excretion ~90% renal
PubChem CID 179344
ChemSpider 156110
Chemical data
Formula C17H16N2O3
296.320 g/mol

Eslicarbazepine acetate (brand names Aptiom, Zebinix, Exalief), abbreviated as ESL, is an anticonvulsant medication approved for use in Europe and the United States as an adjunctive therapy for epilepsy.[citation needed]

Similarly to oxcarbazepine, ESL behaves as a prodrug to eslicarbazepine ((S)-(+)-licarbazepine).[1] As such, their mechanisms of action are identical.[2] However, there may be pharmacokinetic differences between the two drugs; for instance, ESL may not produce as high of peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine, which could, in theory, improve tolerability.[citation needed]

Like oxcarbazepine, ESL may be used to treat bipolar disorder and trigeminal neuralgia.

See also


  1. ^ Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–94. PMC 1562526. PMID 16621450. doi:10.1016/j.eplepsyres.2006.02.004. 
  2. ^ Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nat. Rev. Neurosci. 5 (7): 553–64. PMID 15208697. doi:10.1038/nrn1430. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.